Zealand Pharma Ownership
Who are the major shareholders and have insiders been buying or selling?
Recent Insider Transactions
Date | Value | Name | Entity | Role | Shares | Max Price |
---|---|---|---|---|---|---|
08 Nov 24 | SellDKK 1,273,500 | Anneline Nansen | Individual | 1,500 | DKK 850.00 | |
29 Aug 24 | SellDKK 30,730,000 | Adam Steensberg | Individual | 35,000 | DKK 878.00 | |
22 Mar 24 | SellDKK 1,424,000 | Nikolaj Barfoed Beck | Individual | 2,000 | DKK 712.00 | |
15 Mar 24 | SellDKK 349,500 | Jens Stenvang | Individual | 500 | DKK 699.00 | |
08 Mar 24 | SellDKK 739,000 | Anneline Nansen | Individual | 1,000 | DKK 739.00 |
Insider Trading Volume
Insider Buying: ZEAL insiders have only sold shares in the past 3 months.
Ownership Breakdown
Owner Type | Number of Shares | Ownership Percentage |
---|---|---|
Individual Insiders | 193,961 | 0.275% |
VC/PE Firms | 6,874,960 | 9.73% |
General Public | 27,946,838 | 39.6% |
Institutions | 35,631,179 | 50.4% |
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21%.
Top Shareholders
Ownership | Name | Shares | Current Value | Change % | Portfolio % | |
---|---|---|---|---|---|---|
6,874,960 | DKK 5.5b | 0% | 66.13% | |||
3,438,184 | DKK 2.8b | 0% | 5.4% | |||
3,138,798 | DKK 2.5b | 0% | 1.23% | |||
3,095,511 | DKK 2.5b | 0% | 0.96% | |||
2,598,972 | DKK 2.1b | 0.07% | no data | |||
2,291,494 | DKK 1.8b | 0% | 0.01% | |||
2,116,494 | DKK 1.7b | 3.1% | no data | |||
1,982,512 | DKK 1.6b | 0% | 0.01% | |||
1,835,158 | DKK 1.5b | 0% | 0.02% | |||
1,528,412 | DKK 1.2b | 0.22% | 0.07% | |||
1,287,750 | DKK 1.0b | -2.39% | 0.21% | |||
929,267 | DKK 745.7m | -28.3% | 1.55% | |||
894,738 | DKK 718.0m | 0% | 0.03% | |||
707,425 | DKK 567.7m | 16.4% | 0.19% | |||
686,189 | DKK 550.7m | -1.59% | 0.01% | |||
594,894 | DKK 477.4m | -16.4% | 0.04% | |||
586,457 | DKK 470.6m | -42.5% | 0.02% | |||
558,118 | DKK 447.9m | 1.39% | 0.01% | |||
518,022 | DKK 415.7m | 0.76% | 0.04% | |||
495,706 | DKK 397.8m | 36.4% | 0.04% | |||
433,445 | DKK 347.8m | 767% | no data | |||
402,000 | DKK 322.6m | 0% | 0.38% | |||
350,322 | DKK 281.1m | 0% | 0.03% | |||
348,429 | DKK 279.6m | 2.53% | 0.38% | |||
298,399 | DKK 239.5m | -12.9% | no data |
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/18 07:05 |
End of Day Share Price | 2024/12/18 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zealand Pharma A/S is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Kerry Holford | Berenberg |
Laura Hindley | Berenberg |
Charlie Haywood | BofA Global Research |